CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05252416
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:54.950299+00:00
Published At: 2025-11-28T00:00:00+00:00
Record Updated At: 2025-11-28
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Advanced Solid Tumors", "HR+ Breast Cancer", "CCNE1 Amplification", "HER2-negative Breast Cancer", "Ovarian Cancer", "Endometrial Cancer", "Gastric Cancer", "Esophageal Adenocarcinoma", "Carcinosarcoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-11-28"
protocolSection.identificationModule.nctId: "NCT05252416"
protocolSection.identificationModule.officialTitle: "A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.